MDElliottMD: home-claude category backfill (parser-claude gap closure)

2026-05-23T10:43:39Z

home-claude category backfill (parser-claude gap closure)

← Older revision		Revision as of 10:43, 23 May 2026
Line 21:		Line 21:
	== References ==		== References ==
	<references />		<references />
			[[Category:Corticosteroids]]
			[[Category:Glucocorticoids]]
			[[Category:Immunosuppressants]]

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #246

2026-05-23T04:04:21Z

parser-claude batch MedTemplate pre-fill, Top 300 #246

New page

{{MedTemplate
| generic = Dexamethasone
| brand = Decadron (historical), Dexpak (taper pack), Hemady, Ozurdex (intravitreal)
| structure =
| classes = [[:Category:Corticosteroids|Corticosteroid]], [[:Category:Glucocorticoids|Glucocorticoid (long-acting, high-potency)]], [[:Category:Immunosuppressants|Immunosuppressant]]
| uses = <vote slug="cerebral-edema-use">Cerebral edema (brain tumors, neurosurgery)</vote>, <vote slug="multiple-myeloma-use">Multiple myeloma (combination chemotherapy backbone)</vote>, <vote slug="bacterial-meningitis-use">Adjunctive bacterial meningitis (early)</vote>, <vote slug="severe-covid-use">Severe COVID-19 requiring oxygen (RECOVERY trial)</vote>, <vote slug="cinv-use">Chemotherapy-induced nausea and vomiting</vote>, <vote slug="croup-use">Croup</vote>, <vote slug="ards-use">ARDS (selected protocols)</vote>, <vote slug="dexamethasone-suppression-test-use">Dexamethasone suppression test (Cushing's diagnosis)</vote>
| starting_dose = Indication-specific: 0.5-9 mg PO/IV daily for inflammation; 4 mg IV q6h for cerebral edema; 40 mg PO once weekly in MM; 6 mg PO/IV daily ×10 days for severe COVID-19; 0.6 mg/kg PO single dose for croup (max 16 mg)
| preparations = 0.5, 0.75, 1, 1.5, 2, 4, 6 mg tablets; oral solution; 4, 10, 20, 100 mg/mL IV; intravitreal implant (Ozurdex)
| fda_max = Indication-specific
| pill_id =
| routes = Oral, IV, IM, intra-articular, intrathecal (rare), intravitreal
| onset = Hours
| duration = Biologic 36-72 hours (long-acting)
| halflife = Plasma ~3-4.5 hours; biologic ~36-72 hours<ref name="decadron-label">FDA Prescribing Information, dexamethasone tablets, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/011664s065lbl.pdf</ref>
| bioavailability = ~80% (oral)<ref name="decadron-label" />
| pregnancy = Used in antenatal lung maturation (24-34 weeks gestation; 6 mg IM q12h × 4 doses); broader use weighs benefits against fetal HPA suppression.{{citation needed}}
| legal = [[USLegal:Prescription only|Rx-only]] in US
| mechanism = <vote slug="dexamethasone-mech-claim">Dexamethasone is a synthetic fluorinated glucocorticoid with ~25-30× the potency of hydrocortisone, virtually no mineralocorticoid activity, and the longest biologic half-life of the routinely used glucocorticoids (36-72 hours).</vote> Activates the glucocorticoid receptor to broadly remodel inflammatory, immune, and metabolic transcription. The lack of mineralocorticoid effect makes it the preferred high-dose glucocorticoid for situations where sodium/water retention is undesirable (cerebral edema, CHF) but unsuitable as adrenal replacement<ref name="decadron-label" />.
}}

== References ==
<references />

Dexamethasone - Revision history

MDElliottMD: home-claude category backfill (parser-claude gap closure)

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #246